ES2715710T3 - Folistatina en el tratamiento de la distrofía muscular de Duchenne - Google Patents
Folistatina en el tratamiento de la distrofía muscular de Duchenne Download PDFInfo
- Publication number
- ES2715710T3 ES2715710T3 ES14706362T ES14706362T ES2715710T3 ES 2715710 T3 ES2715710 T3 ES 2715710T3 ES 14706362 T ES14706362 T ES 14706362T ES 14706362 T ES14706362 T ES 14706362T ES 2715710 T3 ES2715710 T3 ES 2715710T3
- Authority
- ES
- Spain
- Prior art keywords
- folistatin
- recombinant
- protein
- muscle
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 title claims abstract description 76
- 238000011282 treatment Methods 0.000 title description 32
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 182
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 175
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 60
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 57
- 150000001413 amino acids Chemical class 0.000 claims abstract description 43
- 238000000034 method Methods 0.000 claims abstract description 30
- 208000024891 symptom Diseases 0.000 claims abstract description 25
- 230000002829 reductive effect Effects 0.000 claims abstract description 10
- 230000003111 delayed effect Effects 0.000 claims abstract description 6
- 210000003205 muscle Anatomy 0.000 claims description 138
- 108020001507 fusion proteins Proteins 0.000 claims description 75
- 102000037865 fusion proteins Human genes 0.000 claims description 75
- 229920001184 polypeptide Polymers 0.000 claims description 43
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 43
- 108010059616 Activins Proteins 0.000 claims description 35
- 239000000488 activin Substances 0.000 claims description 35
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims description 34
- 108010056852 Myostatin Proteins 0.000 claims description 34
- 102100026818 Inhibin beta E chain Human genes 0.000 claims description 32
- 238000001727 in vivo Methods 0.000 claims description 30
- 210000004027 cell Anatomy 0.000 claims description 24
- 150000007523 nucleic acids Chemical class 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 230000009467 reduction Effects 0.000 claims description 14
- 230000001965 increasing effect Effects 0.000 claims description 13
- 230000006870 function Effects 0.000 claims description 12
- 230000005764 inhibitory process Effects 0.000 claims description 12
- 230000017074 necrotic cell death Effects 0.000 claims description 12
- 206010048654 Muscle fibrosis Diseases 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 210000004962 mammalian cell Anatomy 0.000 claims description 9
- 206010028320 muscle necrosis Diseases 0.000 claims description 9
- 230000006866 deterioration Effects 0.000 claims description 7
- 206010028289 Muscle atrophy Diseases 0.000 claims description 6
- 125000000539 amino acid group Chemical group 0.000 claims description 6
- 230000009756 muscle regeneration Effects 0.000 claims description 6
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 claims description 5
- 101710194452 Growth/differentiation factor 11 Proteins 0.000 claims description 5
- 208000010428 Muscle Weakness Diseases 0.000 claims description 5
- 206010028372 Muscular weakness Diseases 0.000 claims description 5
- 230000001976 improved effect Effects 0.000 claims description 5
- 201000000585 muscular atrophy Diseases 0.000 claims description 5
- 210000005260 human cell Anatomy 0.000 claims description 4
- 230000004202 respiratory function Effects 0.000 claims description 4
- 206010039722 scoliosis Diseases 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 206010023201 Joint contracture Diseases 0.000 claims description 3
- 230000006741 behavioral dysfunction Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 208000028867 ischemia Diseases 0.000 claims description 3
- 230000004199 lung function Effects 0.000 claims description 3
- 230000003387 muscular Effects 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 208000028698 Cognitive impairment Diseases 0.000 claims description 2
- 208000019505 Deglutition disease Diseases 0.000 claims description 2
- 230000017531 blood circulation Effects 0.000 claims description 2
- 230000019771 cognition Effects 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 157
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 69
- 235000001014 amino acid Nutrition 0.000 description 49
- 238000002347 injection Methods 0.000 description 46
- 239000007924 injection Substances 0.000 description 46
- 241001465754 Metazoa Species 0.000 description 41
- 210000002966 serum Anatomy 0.000 description 40
- 201000010099 disease Diseases 0.000 description 37
- 230000000694 effects Effects 0.000 description 31
- 241000699670 Mus sp. Species 0.000 description 30
- 208000035475 disorder Diseases 0.000 description 30
- 210000001519 tissue Anatomy 0.000 description 25
- 239000000203 mixture Substances 0.000 description 24
- 230000035772 mutation Effects 0.000 description 24
- 239000003981 vehicle Substances 0.000 description 24
- 201000006938 muscular dystrophy Diseases 0.000 description 21
- 210000001087 myotubule Anatomy 0.000 description 20
- 210000002027 skeletal muscle Anatomy 0.000 description 18
- 210000003699 striated muscle Anatomy 0.000 description 18
- 230000037430 deletion Effects 0.000 description 17
- 238000012217 deletion Methods 0.000 description 17
- 230000004761 fibrosis Effects 0.000 description 16
- 238000006467 substitution reaction Methods 0.000 description 16
- 230000000875 corresponding effect Effects 0.000 description 14
- 206010016654 Fibrosis Diseases 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 210000002460 smooth muscle Anatomy 0.000 description 13
- 206010020880 Hypertrophy Diseases 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 230000011664 signaling Effects 0.000 description 11
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 10
- 230000037396 body weight Effects 0.000 description 10
- 125000006850 spacer group Chemical group 0.000 description 10
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 9
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 9
- 108091006020 Fc-tagged proteins Proteins 0.000 description 9
- 206010028851 Necrosis Diseases 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 229940112869 bone morphogenetic protein Drugs 0.000 description 9
- 108010069091 Dystrophin Proteins 0.000 description 8
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 8
- 239000005089 Luciferase Substances 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000009885 systemic effect Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 102000012422 Collagen Type I Human genes 0.000 description 7
- 108010022452 Collagen Type I Proteins 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 229920000669 heparin Polymers 0.000 description 7
- 229960002897 heparin Drugs 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000000670 limiting effect Effects 0.000 description 7
- 230000037257 muscle growth Effects 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 238000010254 subcutaneous injection Methods 0.000 description 7
- 239000007929 subcutaneous injection Substances 0.000 description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 6
- 102000001039 Dystrophin Human genes 0.000 description 6
- 108010090290 Growth Differentiation Factor 2 Proteins 0.000 description 6
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 description 6
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 6
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 6
- 206010028311 Muscle hypertrophy Diseases 0.000 description 6
- 101000828148 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Transposon Ty3-G Gag polyprotein Proteins 0.000 description 6
- 101000790437 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Transposon Ty3-I Gag polyprotein Proteins 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 210000003128 head Anatomy 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 6
- 230000012042 muscle hypertrophy Effects 0.000 description 6
- 210000004165 myocardium Anatomy 0.000 description 6
- 230000007170 pathology Effects 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 5
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 5
- 108010029485 Protein Isoforms Proteins 0.000 description 5
- 102000001708 Protein Isoforms Human genes 0.000 description 5
- 108700019146 Transgenes Proteins 0.000 description 5
- 230000003187 abdominal effect Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000008030 elimination Effects 0.000 description 5
- 238000003379 elimination reaction Methods 0.000 description 5
- 238000007918 intramuscular administration Methods 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 230000002035 prolonged effect Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000002699 waste material Substances 0.000 description 5
- 102100028726 Bone morphogenetic protein 10 Human genes 0.000 description 4
- 101710118482 Bone morphogenetic protein 10 Proteins 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 239000004606 Fillers/Extenders Substances 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 210000003414 extremity Anatomy 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 210000001255 hallux Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 238000009163 protein therapy Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000002747 voluntary effect Effects 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- UBWXUGDQUBIEIZ-UHFFFAOYSA-N (13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl) 3-phenylpropanoate Chemical compound CC12CCC(C3CCC(=O)C=C3CC3)C3C1CCC2OC(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-UHFFFAOYSA-N 0.000 description 3
- 102000005606 Activins Human genes 0.000 description 3
- 201000006935 Becker muscular dystrophy Diseases 0.000 description 3
- 208000031229 Cardiomyopathies Diseases 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 3
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 3
- 102000016970 Follistatin Human genes 0.000 description 3
- 108010014612 Follistatin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 101000690429 Panax ginseng Floral homeotic protein AGAMOUS Proteins 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000002869 basic local alignment search tool Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000003766 bioinformatics method Methods 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 238000013401 experimental design Methods 0.000 description 3
- 229940028334 follicle stimulating hormone Drugs 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 210000002414 leg Anatomy 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000000663 muscle cell Anatomy 0.000 description 3
- 229940037201 oris Drugs 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 210000003314 quadriceps muscle Anatomy 0.000 description 3
- 210000000664 rectum Anatomy 0.000 description 3
- 239000013074 reference sample Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000007910 systemic administration Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 210000003371 toe Anatomy 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 description 2
- 102000004420 Creatine Kinase Human genes 0.000 description 2
- 108010042126 Creatine kinase Proteins 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 102100025682 Dystroglycan 1 Human genes 0.000 description 2
- 108010071885 Dystroglycans Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 238000000729 Fisher's exact test Methods 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 206010068871 Myotonic dystrophy Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000008228 bacteriostatic water for injection Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 208000028831 congenital heart disease Diseases 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 210000004090 human X chromosome Anatomy 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003601 intercostal effect Effects 0.000 description 2
- 230000003447 ipsilateral effect Effects 0.000 description 2
- 230000009191 jumping Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 210000003632 microfilament Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- -1 or others Chemical compound 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000009183 running Effects 0.000 description 2
- 210000002235 sarcomere Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010052946 Activin Receptors Proteins 0.000 description 1
- 102000018918 Activin Receptors Human genes 0.000 description 1
- 102100027647 Activin receptor type-2B Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 101100322085 Arabidopsis thaliana CAC3 gene Proteins 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 101150041731 CAC2 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- 206010013642 Drooling Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100034239 Emerin Human genes 0.000 description 1
- 201000009344 Emery-Dreifuss muscular dystrophy Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000031969 Eye Hemorrhage Diseases 0.000 description 1
- 208000037149 Facioscapulohumeral dystrophy Diseases 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000605403 Homo sapiens Plasminogen Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000015580 Increased body weight Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 208000020358 Learning disease Diseases 0.000 description 1
- 208000007623 Lordosis Diseases 0.000 description 1
- 241000489861 Maximus Species 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 208000034819 Mobility Limitation Diseases 0.000 description 1
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 1
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 1
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 1
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101000822667 Mus musculus Something about silencing protein 10 Proteins 0.000 description 1
- 206010061533 Myotonia Diseases 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 241000223503 Platysma Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 241000242739 Renilla Species 0.000 description 1
- 108010052090 Renilla Luciferases Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101100514477 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MSI1 gene Proteins 0.000 description 1
- 208000008630 Sialorrhea Diseases 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- 208000037140 Steinert myotonic dystrophy Diseases 0.000 description 1
- 208000031439 Striae Distensae Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 241000826860 Trapezium Species 0.000 description 1
- 244000000188 Vaccinium ovalifolium Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000007488 abnormal function Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 210000001361 achilles tendon Anatomy 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 108010023082 activin A Proteins 0.000 description 1
- 108010057453 activin receptor type II-B Proteins 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000006736 behavioral deficit Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 150000003938 benzyl alcohols Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000001314 canonical amino-acid group Chemical group 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000002802 cardiorespiratory effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 210000000852 deltoid muscle Anatomy 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 210000000188 diaphragm Anatomy 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 206010013932 dyslexia Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001856 erectile effect Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 208000008570 facioscapulohumeral muscular dystrophy Diseases 0.000 description 1
- 210000000109 fascia lata Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 210000002082 fibula Anatomy 0.000 description 1
- 210000003811 finger Anatomy 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 210000001733 follicular fluid Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000004932 little finger Anatomy 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000018984 mastication Effects 0.000 description 1
- 238000010077 mastication Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000001002 morphogenetic effect Effects 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 210000003365 myofibril Anatomy 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 201000009340 myotonic dystrophy type 1 Diseases 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003188 neurobehavioral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 208000029278 non-syndromic brachydactyly of fingers Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000002976 pectoralis muscle Anatomy 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 1
- 229960000244 procainamide Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 208000026526 progressive weakness Diseases 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 239000004248 saffron Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000001991 scapula Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000001088 stapedius Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000013179 statistical model Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000009120 supportive therapy Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229940124598 therapeutic candidate Drugs 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 210000003454 tympanic membrane Anatomy 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000007497 verbal memory Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000021542 voluntary musculoskeletal movement Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4707—Muscular dystrophy
- C07K14/4708—Duchenne dystrophy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Marine Sciences & Fisheries (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361756996P | 2013-01-25 | 2013-01-25 | |
| US201361915733P | 2013-12-13 | 2013-12-13 | |
| PCT/US2014/012996 WO2014116981A1 (en) | 2013-01-25 | 2014-01-24 | Follistatin in treating duchenne muscular dystrophy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2715710T3 true ES2715710T3 (es) | 2019-06-05 |
Family
ID=50159515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14706362T Active ES2715710T3 (es) | 2013-01-25 | 2014-01-24 | Folistatina en el tratamiento de la distrofía muscular de Duchenne |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9957309B2 (https=) |
| EP (1) | EP2948161B1 (https=) |
| JP (2) | JP6475639B2 (https=) |
| KR (1) | KR102253597B1 (https=) |
| CN (1) | CN104902915B (https=) |
| AU (2) | AU2014209178B2 (https=) |
| CA (1) | CA2898121A1 (https=) |
| EA (1) | EA201590719A1 (https=) |
| ES (1) | ES2715710T3 (https=) |
| IL (1) | IL240024B (https=) |
| MX (1) | MX362105B (https=) |
| WO (1) | WO2014116981A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| TWI782836B (zh) | 2007-02-02 | 2022-11-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
| AU2009262970A1 (en) | 2008-06-26 | 2009-12-30 | Acceleron Pharma Inc. | Methods for dosing an activin-ActRIIa antagonist and monitoring of treated patients |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| EA201590719A1 (ru) * | 2013-01-25 | 2015-12-30 | Шир Хьюман Дженетик Терапис, Инк. | Фоллистатин в лечении мышечной дистрофии дюшенна |
| PT2971039T (pt) | 2013-03-14 | 2020-05-06 | Immusoft Corp | Métodos para diferenciação e transdução in vitro de células b de memória com vetores virais pseudotipados vsv-g |
| US10010498B2 (en) | 2014-06-04 | 2018-07-03 | Acceleron Pharma Inc. | Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins |
| US10023621B2 (en) * | 2014-06-04 | 2018-07-17 | Acceleron Pharma Inc. | Follistatin-related fusion proteins |
| AU2016238254B2 (en) * | 2015-03-26 | 2022-05-05 | Acceleron Pharma Inc. | Follistatin-related fusion proteins and uses thereof |
| CA3010599C (en) * | 2016-01-06 | 2025-05-20 | Stealth Biotherapeutics Inc. | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY |
| WO2017152090A2 (en) * | 2016-03-04 | 2017-09-08 | Shire Human Genetic Therapies, Inc. | Recombinant follistatin-fc fusion proteins and use in treating duchenne muscular dystrophy |
| JP2020519291A (ja) * | 2017-05-12 | 2020-07-02 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | 組み換えフォリスタチン−ｆｃ融合タンパク質およびデュシェンヌ型筋ジストロフィーの治療における使用 |
| KR101822633B1 (ko) * | 2017-08-22 | 2018-01-26 | (주)진셀팜 | 폴리스타틴 유래 생리활성 펩타이드, 및 이의 용도 |
| WO2019046903A1 (en) * | 2017-09-08 | 2019-03-14 | Baker Heart and Diabetes Institute | THERAPEUTIC METHOD FOR INCREASING MUSCLE MASS IN A SUBJECT |
| CN111936617A (zh) * | 2018-03-16 | 2020-11-13 | 益缪索夫特公司 | 经遗传工程化以分泌卵泡抑素的b细胞以及使用所述b细胞来治疗卵泡抑素相关的疾病、病况、病症及增强肌肉生长和力量的方法 |
| WO2019191204A1 (en) * | 2018-03-28 | 2019-10-03 | Acceleron Pharma Inc. | Follistatin polypeptides for the treatment of muscle contracture |
| CA3094859A1 (en) * | 2020-10-01 | 2022-04-01 | Entos Pharmaceuticals Inc. | Proteolipid vesicles formulated with fusion associated small transmembrane proteins |
| KR102361657B1 (ko) | 2021-04-26 | 2022-02-14 | 주식회사 케이에스비튜젠 | 14-디옥시-11,12-디디히드로안드로그라폴라이드 석시네이트를 유효성분으로 함유하는 듀센형 근이영양증을 포함한 유전성 근육질환의 예방 또는 치료용 조성물 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| BR0307871A (pt) | 2002-02-21 | 2005-04-12 | Wyeth Corp | Proteìnas contendo domìnio de folistatina |
| US7355018B2 (en) | 2003-09-30 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Modified IGF1 polypeptides with increased stability and potency |
| JP4688483B2 (ja) * | 2004-04-15 | 2011-05-25 | 株式会社テクノネットワーク四国 | フォリスタチン変異体ポリペプチド |
| WO2006130834A2 (en) | 2005-05-31 | 2006-12-07 | Board Of Regents, The University Of Texas System | IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF |
| WO2008030367A2 (en) * | 2006-09-01 | 2008-03-13 | The General Hospital Corporation | Selective myostatin inhibitors |
| JP5773868B2 (ja) * | 2008-06-26 | 2015-09-02 | アクセルロン ファーマ， インコーポレイテッド | アクチビン−ＡｃｔＲＩＩａのアンタゴニストおよび赤血球レベルを高めるためのその使用 |
| AU2009262970A1 (en) | 2008-06-26 | 2009-12-30 | Acceleron Pharma Inc. | Methods for dosing an activin-ActRIIa antagonist and monitoring of treated patients |
| BR112012005225B8 (pt) * | 2009-09-09 | 2023-01-10 | Acceleron Pharma Inc | Uso de uma proteína de fusão actriib-fc para o tratamento de um transtorno relacionado ao osso ou associado à perda de músculo por crescimento muscular insuficiente |
| US9023890B2 (en) * | 2009-12-02 | 2015-05-05 | The Charlotte-Mecklenburg Hospital Authority | Nitrate esters and their use for the treatment of muscle and muscle related diseases |
| US8580922B2 (en) * | 2011-03-04 | 2013-11-12 | Shire Human Genetic Therapies, Inc. | Peptide linkers for polypeptide compositions and methods for using same |
| EP2861617A1 (en) | 2012-06-15 | 2015-04-22 | Pfizer Inc. | Improved antagonist antibodies against gdf-8 and uses therefor |
| TWI633117B (zh) | 2012-09-13 | 2018-08-21 | 必治妥美雅史谷比公司 | 結合至肌肉生長抑制素（ｍｙｏｓｔａｔｉｎ）以纖維連接蛋白爲主之支架結構域蛋白質 |
| EA201590719A1 (ru) * | 2013-01-25 | 2015-12-30 | Шир Хьюман Дженетик Терапис, Инк. | Фоллистатин в лечении мышечной дистрофии дюшенна |
| WO2014187807A1 (en) | 2013-05-21 | 2014-11-27 | Arcarios B.V. | Follistatin derivatives |
| US10023621B2 (en) | 2014-06-04 | 2018-07-17 | Acceleron Pharma Inc. | Follistatin-related fusion proteins |
| WO2016057975A2 (en) | 2014-10-10 | 2016-04-14 | Research Institute At Nationwide Children's Hospital | Guided injections for aav gene transfer to muscle |
-
2014
- 2014-01-24 EA EA201590719A patent/EA201590719A1/ru unknown
- 2014-01-24 ES ES14706362T patent/ES2715710T3/es active Active
- 2014-01-24 KR KR1020157016986A patent/KR102253597B1/ko not_active Expired - Fee Related
- 2014-01-24 AU AU2014209178A patent/AU2014209178B2/en not_active Ceased
- 2014-01-24 US US14/762,373 patent/US9957309B2/en not_active Expired - Fee Related
- 2014-01-24 MX MX2015009631A patent/MX362105B/es active IP Right Grant
- 2014-01-24 WO PCT/US2014/012996 patent/WO2014116981A1/en not_active Ceased
- 2014-01-24 EP EP14706362.2A patent/EP2948161B1/en active Active
- 2014-01-24 CN CN201480003715.0A patent/CN104902915B/zh not_active Expired - Fee Related
- 2014-01-24 JP JP2015555353A patent/JP6475639B2/ja not_active Expired - Fee Related
- 2014-01-24 CA CA2898121A patent/CA2898121A1/en not_active Abandoned
-
2015
- 2015-07-20 IL IL240024A patent/IL240024B/en not_active IP Right Cessation
-
2018
- 2018-04-12 US US15/951,929 patent/US10723772B2/en not_active Expired - Fee Related
- 2018-10-30 JP JP2018203613A patent/JP2019059730A/ja active Pending
-
2019
- 2019-02-06 AU AU2019200797A patent/AU2019200797B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016511751A (ja) | 2016-04-21 |
| AU2014209178A1 (en) | 2015-05-21 |
| AU2019200797A1 (en) | 2019-02-21 |
| CN104902915A (zh) | 2015-09-09 |
| EP2948161B1 (en) | 2018-12-12 |
| JP2019059730A (ja) | 2019-04-18 |
| EA201590719A1 (ru) | 2015-12-30 |
| IL240024B (en) | 2020-05-31 |
| AU2019200797B2 (en) | 2021-03-04 |
| US10723772B2 (en) | 2020-07-28 |
| US20180305421A1 (en) | 2018-10-25 |
| HK1217637A1 (en) | 2017-01-20 |
| EP2948161A1 (en) | 2015-12-02 |
| CN104902915B (zh) | 2018-07-06 |
| MX2015009631A (es) | 2015-11-30 |
| KR20150111347A (ko) | 2015-10-05 |
| IL240024A0 (en) | 2015-09-24 |
| CA2898121A1 (en) | 2014-07-31 |
| US20160083440A1 (en) | 2016-03-24 |
| MX362105B (es) | 2019-01-04 |
| WO2014116981A1 (en) | 2014-07-31 |
| US9957309B2 (en) | 2018-05-01 |
| KR102253597B1 (ko) | 2021-05-17 |
| JP6475639B2 (ja) | 2019-02-27 |
| HK1213804A1 (zh) | 2016-07-15 |
| AU2014209178B2 (en) | 2018-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2715710T3 (es) | Folistatina en el tratamiento de la distrofía muscular de Duchenne | |
| ES2676406T3 (es) | Anticuerpos anti-Flt-1 en el tratamiento de la distrofia muscular de Duchenne | |
| CN110914294A (zh) | 重组卵泡抑素-fc融合蛋白及其在治疗杜氏肌营养不良中的用途 | |
| US20200247856A1 (en) | Recombinant follistatin-fc fusion proteins and use in treating duchenne muscular dystrophy | |
| EP2948164B1 (en) | Placenta growth factor in treating duchenne muscular dystrophy | |
| HK1217637B (en) | Follistatin in treating duchenne muscular dystrophy | |
| HK1213804B (zh) | 治疗杜兴氏肌营养不良的卵泡抑素 | |
| HK1217710B (en) | Anti-flt-1 antibodies in treating duchenne muscular dystrophy |